Genitourinary Syndrome of Menopause (GSM)
12
5
6
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
8%
1 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (12)
Via, a Hyaluronic Acid (HLA) Based Vaginal Moisturizer Study
Determining the Extent of the Genitourinary Syndrome of Menopause Burden in Breast Cancer Survivors
Pilot Study of Individualized Treatment for Genitourinary Syndrome of Menopause in Women After Cancer Treatment
Bipolar Radiofrequency for Genitourinary Syndrome of Menopause
ASSIST-VLA: Assessment of Symptom-Specific Improvement in Diagnosed Vaginal Atrophy Following Laser Therapy
A Clinical Study of Chinese Herbal Formula TJAOA103 in Treating Genitourinary Syndrome of Menopause
Efficacy of Non-ablative Radiofrequency Combined With Pelvic Floor Muscle Training for Genitourinary Syndrome of Menopause in Breast Cancer Survivors (RF-SGM)
Elastographic Improvement of Vaginal Atrophy Treated by Erbium Yag Laser
Genitourinary Syndrome of Menopause in Breast Cancer
Treatment of Vulvo-vaginal Atrophy (VVA) Using Vaginal Dilator in Addition to Usual Treatment
A Randomized, Single Center Pilot Study Comparing Hyaluronic Acid to Vaginal Estrogen for Treatment of Genitourinary Syndrome of Menopause
To Assess Signs and Symptoms in Women Affected by GSM After One Cycle of Pixel CO2-Alma Fractionated Laser